Hasnain Faheem 4

What Happened Hasnain Faheem, President & CEO and a director of Gossamer Bio (GOSS), had certain outstanding stock options cancelled and reissued as part of a one-time option repricing effective March 19, 2026. The filing shows dispositions to the issuer (cancellations) and concurrent grants (new awards) totaling 7,124,500 option shares. Per the company footnote, the new (repriced) options carry an exercise price of $0.45 each; the Form 4 lists these as derivative transactions with N/A for per-share transaction price because this is a repricing/regrant rather than a market sale or purchase.

Key Details

• Transaction date: March 19, 2026; Form 4 filed March 20, 2026 (timely filing).
• Total options cancelled and re-granted: 7,124,500 shares (sum of multiple individual dispositions and grants reported).
• New exercise price for the repriced options: $0.45 per share (per footnote F1).
• Shares owned after transaction: not specified in the reported entries.
• Footnotes: F1 — one-time repricing approved, exercise price reduced to $0.45; all other terms (including vesting and term) remain unchanged except as modified by the repricing. F2 — the new awards are issued under the 2019 Incentive Award Plan and vest according to the award agreements and prior Form 4 disclosures, subject to continued service.
• Filing timeliness: filed next business day after the repricing date (no late filing flagged).

Context This filing documents a repricing and regrant of derivative awards (options), not a cash purchase or open-market sale. The transaction does not itself indicate immediate exercise or sale of shares; vesting and exercise remain subject to the original award terms unless otherwise modified. For retail investors, repricings can affect potential future dilution and the incentive alignment of executives, but they are administrative changes to option economics rather than direct insider buying or selling of stock.